Trihexiphenidyl Hydrochlorid Tablet Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 2mg
Reference Brands: Artane (USA/EU/India), Parkin (india/LATAM)
Category:
Antipsychotropic Drugs
Trihexyphenidyl is used alone or together with other medicines (e.g., levodopa) to treat Parkinson's disease. By improving muscle control and reducing stiffness, this medicine allows more normal movements of the body as the disease symptoms are reduced.
Trihexiphenidyl Hydrochlorid Tablet is available in Tablets
and strengths such as 2mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Trihexiphenidyl Hydrochlorid Tablet is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Trihexiphenidyl Hydrochlorid Tablet can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Trihexyphenidyl is an anticholinergic medication widely used to manage the motor symptoms associated with Parkinson’s disease, including tremors, muscle stiffness, spasms, and poor muscle control. It works by blocking the neurotransmitter acetylcholine in the central nervous system, helping restore the balance between acetylcholine and dopamine, which improves voluntary muscle movement and reduces involuntary motor symptoms.
Approved by the FDA in June 2003 for idiopathic, postencephalitic, and arteriosclerotic Parkinsonism, Trihexyphenidyl is also effective in treating movement disorders caused by certain central nervous system (CNS) medications such as fluphenazine, haloperidol, and chlorpromazine. It is typically administered orally in tablet form, with dosage tailored to the severity of symptoms and patient tolerance.
Trihexyphenidyl’s use requires careful monitoring due to potential side effects including dry mouth, blurred vision, constipation, urinary retention, and cognitive impairment. It is contraindicated in patients with narrow-angle glaucoma, gastrointestinal obstruction, or certain cardiovascular conditions. Proper dosing and regular follow-up are essential to minimize toxicity and optimize therapeutic outcomes, making it a critical tool for healthcare professionals managing Parkinsonian and drug-induced extrapyramidal symptoms.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing